Stock Track | Evotec SE Plunges 9.57% Pre-market Following Disappointing Q3 Results and Asset Sale

Stock Track11-05

Shares of Evotec SE (EVO) tumbled 9.57% in pre-market trading on Wednesday, as investors reacted to the company's underwhelming third-quarter financial results and news of a strategic asset sale.

The German biotech firm reported quarterly losses of $0.14 per share, meeting analyst expectations but representing a 16.67% increase in losses compared to the same period last year. More significantly, Evotec's quarterly sales came in at $191.62 million, missing the analyst consensus estimate of $237.32 million by 19.26%. This also marks a 5.71% decrease from the $203.21 million in sales reported in the same quarter of the previous year.

Adding to the market's concerns, Evotec announced the sale of its Just – Evotec Biologics Toulouse site to Sandoz (SDZNY). While this move may be part of a broader strategic realignment, it comes at a time when the company is facing challenges in revenue growth. The combination of missed sales targets and asset divestment appears to have sparked investor unease, contributing to the significant pre-market decline in Evotec's stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121960092?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 17:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121960092","market":"nz","top_or_hot":-1,"title":"Stock Track | Evotec SE Plunges 9.57% Pre-market Following Disappointing Q3 Results and Asset Sale","media":"Stock Track","content":"<p>Shares of Evotec SE (EVO) tumbled 9.57% in pre-market trading on Wednesday, as investors reacted to the company's underwhelming third-quarter financial results and news of a strategic asset sale.</p>\n\n<p>The German biotech firm reported quarterly losses of $0.14 per share, meeting analyst expectations but representing a 16.67% increase in losses compared to the same period last year. More significantly, Evotec's quarterly sales came in at $191.62 million, missing the analyst consensus estimate of $237.32 million by 19.26%. This also marks a 5.71% decrease from the $203.21 million in sales reported in the same quarter of the previous year.</p>\n\n<p>Adding to the market's concerns, Evotec announced the sale of its Just – Evotec Biologics Toulouse site to Sandoz (SDZNY). While this move may be part of a broader strategic realignment, it comes at a time when the company is facing challenges in revenue growth. The combination of missed sales targets and asset divestment appears to have sparked investor unease, contributing to the significant pre-market decline in Evotec's stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Evotec SE Plunges 9.57% Pre-market Following Disappointing Q3 Results and Asset Sale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Evotec SE Plunges 9.57% Pre-market Following Disappointing Q3 Results and Asset Sale\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 17:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Evotec SE (EVO) tumbled 9.57% in pre-market trading on Wednesday, as investors reacted to the company's underwhelming third-quarter financial results and news of a strategic asset sale.</p>\n\n<p>The German biotech firm reported quarterly losses of $0.14 per share, meeting analyst expectations but representing a 16.67% increase in losses compared to the same period last year. More significantly, Evotec's quarterly sales came in at $191.62 million, missing the analyst consensus estimate of $237.32 million by 19.26%. This also marks a 5.71% decrease from the $203.21 million in sales reported in the same quarter of the previous year.</p>\n\n<p>Adding to the market's concerns, Evotec announced the sale of its Just – Evotec Biologics Toulouse site to Sandoz (SDZNY). While this move may be part of a broader strategic realignment, it comes at a time when the company is facing challenges in revenue growth. The combination of missed sales targets and asset divestment appears to have sparked investor unease, contributing to the significant pre-market decline in Evotec's stock price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVO","symbol_name":"Evotec SE","start_time":0,"source_url":"","article_id":"1121960092","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121960092","pubTimestamp":1762333587,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Evotec SE (EVO) tumbled 9.57% in pre-market trading on Wednesday, as investors reacted to the company's underwhelming third-quarter financial results and news of a strategic asset sale....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVO":"Evotec SE"},"translate_title":"个股追踪|第三季度业绩令人失望及资产出售Evotec SE盘前暴跌9.57%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVO":1},"content_text":"Shares of Evotec SE (EVO) tumbled 9.57% in pre-market trading on Wednesday, as investors reacted to the company's underwhelming third-quarter financial results and news of a strategic asset sale.\nThe German biotech firm reported quarterly losses of $0.14 per share, meeting analyst expectations but representing a 16.67% increase in losses compared to the same period last year. More significantly, Evotec's quarterly sales came in at $191.62 million, missing the analyst consensus estimate of $237.32 million by 19.26%. This also marks a 5.71% decrease from the $203.21 million in sales reported in the same quarter of the previous year.\nAdding to the market's concerns, Evotec announced the sale of its Just – Evotec Biologics Toulouse site to Sandoz (SDZNY). While this move may be part of a broader strategic realignment, it comes at a time when the company is facing challenges in revenue growth. The combination of missed sales targets and asset divestment appears to have sparked investor unease, contributing to the significant pre-market decline in Evotec's stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121960092","isCrawlerRequest":true}